Artco /
6 June 2016Americas

AstraZeneca signs Zurampic licensing deal with Grünenthal

Pharmaceutical company AstraZeneca has agreed a licensing deal with German drug maker Grünenthal centring on gout treatment drug Zurampic (lesinurad).

Grünenthal has acquired the rights to the drug in all 28 EU member states as well as in Iceland, Switzerland, Norway and Liechtenstein.

The deal also covers all Latin-American countries including Mexico, the Dominican Republic and Cuba.

The drug helps adult patients with uncontrolled gout.

Under the deal, Grünenthal will pay AstraZeneca up to $230 million and will also pay “tiered, low double-digit royalties” on annual product sales.

Luke Miels, executive vice president, global product and portfolio strategy at AstraZeneca, said: “Grünenthal has an established presence across European and Latin American markets and extensive expertise in inflammatory diseases. This agreement allows us to further focus our resources on our strategic priorities.”

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at